This book offers readers access to a baseline of ‘critical mass’ knowledge in commercial biotech research and development (“R&D”). The clear, concise coverage spans from laboratory bench research to regulatory market approvals for a range of the primary biotech human health products. The discussion includes coverage of the advent of biologics, products derived from living organisms to treat life-threatening and otherwise seriously debilitating diseases, including a range of cancers and Hepatitis C, but at tremendous costs in both development and the delivery of care.

This book is an invaluable reference resource for law, business, and medical school educators and students; biopharmaceutical executives; investors in the field; university and other research institution professionals, such as technology transfer administrators; research scientists; regulators; and the general public with interest in the enormous economic and human health impact of biotechnology.